Eiger BioPharmaceuticals, Inc.
EIGR
EIGR was delisted on the 10th of April, 2024.
40 hedge funds and large institutions have $128M invested in Eiger BioPharmaceuticals, Inc. in 2014 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 9 increasing their positions, 12 reducing their positions, and 6 closing their positions.
100% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 6
75% more capital invested
Capital invested by funds: $73.1M → $128M (+$54.7M)
18% more funds holding
Funds holding: 34 → 40 (+6)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
25% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HighTower Advisors
Chicago,
Illinois
|
+$20.2M |
| 2 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$5.3M |
| 3 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$1.67M |
| 4 |
Axa
Paris,
France
|
+$535K |
| 5 |
RPAM
Rhenman & Partners Asset Management
Stockholm,
Sweden
|
+$510K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$4.55M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$1.71M |
| 3 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$801K |
| 4 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
-$630K |
| 5 |
State Street
Boston,
Massachusetts
|
-$480K |
EIGR Hedge Fund Activity: Q2 2014 in Review
40 of the 3,480 institutional investors tracked by Wall St. Rank reported a position in Eiger BioPharmaceuticals, Inc. (EIGR) for Q2 2014, worth a combined $128M — up 75% from $73.1M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new EIGR positions and 6 closed out — a net gain of 6 holders — while 9 added to existing stakes and 12 trimmed.
The largest buyer was HighTower Advisors, adding an estimated $20.2M. The largest seller was JP Morgan Chase, cutting an estimated $4.55M.
- 40 institutional investors held Eiger BioPharmaceuticals, Inc. (EIGR) as of Q2 2014, up from 34 in Q1 2014.
- Funds reported $128M of Eiger BioPharmaceuticals, Inc. stock for Q2 2014, up 75% quarter-over-quarter.
- 12 funds opened new Eiger BioPharmaceuticals, Inc. positions in Q2 2014 and 6 closed out, a net change of +6 holders.
- The largest Eiger BioPharmaceuticals, Inc. buyer in Q2 2014 was HighTower Advisors, an estimated $20.2M added.
- The largest Eiger BioPharmaceuticals, Inc. seller in Q2 2014 was JP Morgan Chase, an estimated $4.55M sold.
Based on aggregated 13F filings for Q2 2014.